NO20061323L - Kinazolinderivater - Google Patents

Kinazolinderivater

Info

Publication number
NO20061323L
NO20061323L NO20061323A NO20061323A NO20061323L NO 20061323 L NO20061323 L NO 20061323L NO 20061323 A NO20061323 A NO 20061323A NO 20061323 A NO20061323 A NO 20061323A NO 20061323 L NO20061323 L NO 20061323L
Authority
NO
Norway
Prior art keywords
formula
quinazoline derivatives
quinazoline
medicament
diseases
Prior art date
Application number
NO20061323A
Other languages
English (en)
Norwegian (no)
Inventor
Laurent Francois And Hennequin
Christopher Thomas Halsall
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34315442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061323(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0321621A external-priority patent/GB0321621D0/en
Priority claimed from GB0406160A external-priority patent/GB0406160D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20061323L publication Critical patent/NO20061323L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20061323A 2003-09-16 2006-03-23 Kinazolinderivater NO20061323L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0321621A GB0321621D0 (en) 2003-09-16 2003-09-16 Quinazoline derivatives
GB0406160A GB0406160D0 (en) 2004-03-19 2004-03-19 Quinazoline derivatives
PCT/GB2004/003915 WO2005026157A1 (en) 2003-09-16 2004-09-13 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
NO20061323L true NO20061323L (no) 2006-06-09

Family

ID=34315442

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061323A NO20061323L (no) 2003-09-16 2006-03-23 Kinazolinderivater

Country Status (16)

Country Link
US (1) US20070032513A1 (pt)
EP (1) EP1667996B1 (pt)
JP (1) JP2007505871A (pt)
KR (1) KR20070027487A (pt)
AR (1) AR045754A1 (pt)
AU (1) AU2004272346A1 (pt)
BR (1) BRPI0414488A (pt)
CA (1) CA2539049A1 (pt)
DE (1) DE602004022180D1 (pt)
ES (1) ES2328696T3 (pt)
IL (1) IL174257A0 (pt)
MX (1) MXPA06002962A (pt)
NO (1) NO20061323L (pt)
TW (1) TW200524913A (pt)
UY (1) UY28516A1 (pt)
WO (1) WO2005026157A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
US20050043336A1 (en) * 2001-11-03 2005-02-24 Hennequin Laurent Francois Andre Quinazoline derivatives as antitumor agents
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
EP1664028A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives as tyrosine kinase inhibitors
ATE395346T1 (de) 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
EP1664030A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
WO2005070020A2 (en) * 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
DE602005010824D1 (de) 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
ES2537631T3 (es) * 2004-05-27 2015-06-10 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
BRPI0511741A (pt) * 2004-06-04 2008-01-02 Astrazeneca Ab derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
ATE501148T1 (de) * 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
KR20080003334A (ko) * 2005-03-11 2008-01-07 더 리젠트스 오브 더 유니버시티 오브 콜로라도 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
ATE488513T1 (de) * 2005-09-20 2010-12-15 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
JP2009508917A (ja) * 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 抗癌剤としてのキナゾリン誘導体
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007063293A1 (en) * 2005-12-02 2007-06-07 Astrazeneca Ab Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase
EP1957499A1 (en) * 2005-12-02 2008-08-20 AstraZeneca AB 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
WO2009042646A1 (en) * 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CN105330653A (zh) * 2014-08-11 2016-02-17 石药集团中奇制药技术（石家庄）有限公司 喹唑啉衍生物
JP2022502495A (ja) 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用
AU2020328598A1 (en) 2019-08-15 2022-03-03 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
IL303753A (en) 2020-12-18 2023-08-01 Yeda res & development co ltd Preparations for use in the treatment of CHD2 HAPLOINSUFFICIENCY and methods for detection
WO2023054759A1 (ko) * 2021-09-30 2023-04-06 한국화학연구원 2-아미노퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69720965T2 (de) * 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CA2361174C (en) * 1999-02-27 2009-10-27 Boehringer Ingelheim Pharma Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
US20050043336A1 (en) * 2001-11-03 2005-02-24 Hennequin Laurent Francois Andre Quinazoline derivatives as antitumor agents
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7576074B2 (en) * 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
UY28441A1 (es) * 2003-07-29 2005-02-28 Astrazeneca Ab Derivados de quinazolina
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
EP1664028A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives as tyrosine kinase inhibitors
ATE395346T1 (de) * 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
CN1882570B (zh) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005030757A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
DE602005010824D1 (de) * 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
BRPI0511741A (pt) * 2004-06-04 2008-01-02 Astrazeneca Ab derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo

Also Published As

Publication number Publication date
IL174257A0 (en) 2006-08-01
UY28516A1 (es) 2005-04-29
AR045754A1 (es) 2005-11-09
TW200524913A (en) 2005-08-01
AU2004272346A1 (en) 2005-03-24
HK1091479A1 (en) 2007-01-19
KR20070027487A (ko) 2007-03-09
US20070032513A1 (en) 2007-02-08
ES2328696T3 (es) 2009-11-17
JP2007505871A (ja) 2007-03-15
EP1667996B1 (en) 2009-07-22
DE602004022180D1 (de) 2009-09-03
CA2539049A1 (en) 2005-03-24
WO2005026157A1 (en) 2005-03-24
MXPA06002962A (es) 2006-06-14
BRPI0414488A (pt) 2006-11-14
EP1667996A1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
NO20061323L (no) Kinazolinderivater
NO20061322L (no) Kinazolinderivater som tyrosin kinase inhibitorer
NO20061743L (no) Kinazolinderivater
NO20066081L (no) Kinazolinderivater som erbB-reseptortyrosinkinaser
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
NO20061415L (no) Kinazolinderivater
NO20073878L (no) Kinazolinderivater som tyrosin kinase inhibitorer
CY1109681T1 (el) Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora
CY1106405T1 (el) Παραγωγα κουιναζολινης
NO20090631L (no) Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser
SE0402735D0 (sv) Novel compounds
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
NO20061746L (no) Kinazolinderivater som antiproliferative midler
NO20062763L (no) Pyrrolotriazinforbindelser som kinaseinhibitorer
MXPA04004219A (es) Derivados de quinazolina como agentes antitumorales.
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
MXPA04004220A (es) Derivados de quinazolina como agentes antitumorales.
TW200512205A (en) Quinazoline derivatives
GB0112348D0 (en) Compounds
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
IS2855B (is) 4-anilínókínasólínafleiður sem andfjölgunarefni
NO20070681L (no) 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application